Newbury Pharmaceuticals AB (OSTO:NEWBRY) Total Equity: kr31.30 Mil (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NEWBRY Newbury Pharmaceuticals AB OSTO:NEWBRY
41 GF Score
Price kr2.48
GF Value kr3.20
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Newbury Pharmaceuticals AB Total Equity?

Newbury Pharmaceuticals AB OSTO:NEWBRY -4.62% 41 Total Equity is kr31.30 Mil as of Feb. 2026. GuruFocus rates OSTO:NEWBRY with a GF Score™ of 41/100 and a GF Value™ of kr3.20 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Newbury Pharmaceuticals AB's total equity for the quarter that ended in Feb. 2026 was kr31.30 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Newbury Pharmaceuticals AB Total Equity Historical Data

* Premium members only.

The historical data trend for Newbury Pharmaceuticals AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newbury Pharmaceuticals AB Total Equity Chart

Newbury Pharmaceuticals AB Annual Data
Trend Aug21 Aug22 Aug23 Aug24 Aug25
Total Equity
38.47 68.77 49.38 51.92 42.75

Newbury Pharmaceuticals AB Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.78 53.52 42.75 35.85 31.30
OSTO:NEWBRY
41GF Score
Newbury Pharmaceuticals AB OSTO:NEWBRY
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newbury Pharmaceuticals AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Newbury Pharmaceuticals AB's Total Equity for the fiscal year that ended in Aug. 2025 is calculated as

Total Equity=Total Assets(Q: Aug. 2025 )-Total Liabilities(Q: Aug. 2025 )
=77.35-34.596
=42.75

Newbury Pharmaceuticals AB's Total Equity for the quarter that ended in Feb. 2026 is calculated as

Total Equity=Total Assets(Q: Feb. 2026 )-Total Liabilities(Q: Feb. 2026 )
=77.257-45.961
=31.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr31.30 Mil mean?
Newbury Pharmaceuticals AB (OSTO:NEWBRY) has a Total Equity of kr31.30 Mil as of Feb. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Newbury Pharmaceuticals AB and its competitors.
Is Newbury Pharmaceuticals AB's Total Equity too high?
Newbury Pharmaceuticals AB's current Total Equity is kr31.30 Mil. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Total Equity compare to ZTS and UTHR?
Newbury Pharmaceuticals AB's Total Equity of kr31.30 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Newbury Pharmaceuticals AB and its competitors. Newbury Pharmaceuticals AB's current Total Equity is kr31.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB (OSTO:NEWBRY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr3.20, compared to a current price of kr2.48 — trading 22.5% below its estimated fair value. The current Total Equity is kr31.30 Mil. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (OSTO:NEWBRY), the current Total Equity is kr31.30 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newbury Pharmaceuticals AB (OSTO:NEWBRY) Overvalued in 2026?

Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued. The current stock price of kr2.48 is trading 22.5% below its estimated GF Value™ of kr3.20. GuruFocus considers Newbury Pharmaceuticals AB to be Modestly Undervalued.

Key valuation signals for OSTO:NEWBRY:

  • Total Equity: kr31.30 Mil
  • GF Value™: kr3.20 vs. price of kr2.48 (22.5% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the OSTO:NEWBRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newbury Pharmaceuticals AB Business Description

Other Exchanges P52:Germany
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score

Get the complete analysis for OSTO:NEWBRY

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.48
Price
kr3.20
GF Value